JCR Pharmaceuticals Co., Ltd. (TYO:4552)

JCR Pharmaceuticals Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	15,513	18,756	13,278	30,733	26,260	10,973
Short-Term Investments	-	-	-	244	-	220
Cash & Short-Term Investments	15,513	18,756	13,278	30,977	26,260	11,193
Cash Growth	-15.23%	41.26%	-57.14%	17.96%	134.61%	31.73%
Receivables	15,179	14,934	11,137	15,585	8,183	7,977
Inventory	24,028	20,933	18,514	14,636	13,554	8,855
Other Current Assets	3,022	2,958	4,873	990	548	317
Total Current Assets	57,742	57,581	47,802	62,188	48,545	28,342
Property, Plant & Equipment	31,702	30,040	32,681	26,782	17,172	14,875
Long-Term Investments	11,648	9,819	9,443	2,769	3,094	3,573
Other Intangible Assets	3,094	3,496	3,652	2,960	3,232	263
Long-Term Deferred Tax Assets	-	1,288	1,357	2,433	1,739	721
Other Long-Term Assets	1,331	2	2	2	2	1
Total Assets	105,517	102,226	94,937	97,134	73,784	47,775
Accounts Payable	1,321	890	1,563	1,324	2,932	679
Accrued Expenses	634	1,130	1,088	1,004	913	790
Short-Term Debt	20,242	8,950	16,800	15,150	12,850	4,880
Current Portion of Long-Term Debt	-	-	500	-	-	-
Current Portion of Leases	-	-	-	-	-	46
Current Income Taxes Payable	35	4,402	2,836	11,104	2,646	3,388
Other Current Liabilities	16,867	14,763	12,975	13,472	9,687	651
Total Current Liabilities	39,099	30,135	35,762	42,054	29,028	10,434
Long-Term Debt	12,150	14,350	5,500	2,950	5,250	3,800
Long-Term Leases	-	-	-	-	-	31
Other Long-Term Liabilities	372	364	339	173	154	201
Total Liabilities	52,550	45,752	42,525	46,047	35,230	15,196
Common Stock	9,061	9,061	9,061	9,061	9,061	9,061
Additional Paid-In Capital	10,392	10,384	10,384	10,994	10,941	10,891
Retained Earnings	35,374	37,278	34,273	33,241	20,904	15,039
Treasury Stock	-5,070	-2,963	-2,978	-3,600	-3,685	-3,865
Comprehensive Income & Other	2,814	2,417	1,421	1,186	1,159	1,264
Total Common Equity	52,571	56,177	52,161	50,882	38,380	32,390
Minority Interest	396	297	251	205	174	189
Shareholders' Equity	52,967	56,474	52,412	51,087	38,554	32,579
Total Liabilities & Equity	105,517	102,226	94,937	97,134	73,784	47,775
Total Debt	32,392	23,300	22,800	18,100	18,100	8,757
Net Cash (Debt)	-16,879	-4,544	-9,522	12,877	8,160	2,436
Net Cash Growth	-	-	-	57.81%	234.97%	-11.93%
Net Cash Per Share	-135.56	-36.24	-76.27	103.67	65.74	19.64
Filing Date Shares Outstanding	121.82	124.8	124.78	123.76	123.61	123.32
Total Common Shares Outstanding	121.82	124.8	124.78	123.76	123.61	123.32
Working Capital	18,643	27,446	12,040	20,134	19,517	17,908
Book Value Per Share	431.53	450.12	418.04	411.14	310.48	262.66
Tangible Book Value	49,477	52,681	48,509	47,922	35,148	32,127
Tangible Book Value Per Share	406.13	422.11	388.77	387.23	284.34	260.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.